Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Net Margin (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Net Margin readings, the most recent being 803.29% for Q1 2026.

  • On a quarterly basis, Net Margin fell 84202.0% to 803.29% in Q1 2026 year-over-year; TTM through Mar 2026 was 182.39%, a 17456.0% decrease, with the full-year FY2025 number at 0.04%, up 6619.0% from a year prior.
  • Net Margin hit 803.29% in Q1 2026 for Atara Biotherapeutics, up from 2266.02% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 38.73% in Q1 2025 to a low of 33790.5% in Q4 2022.
  • Median Net Margin over the past 5 years was 463.96% (2026), compared with a mean of 3622.0%.
  • The widest YoY moves for Net Margin: up 3254565bps in 2023, down -900276bps in 2023.
  • Atara Biotherapeutics' Net Margin stood at 33790.5% in 2022, then skyrocketed by 96bps to 1244.85% in 2023, then soared by 97bps to 38.75% in 2024, then crashed by -5747bps to 2266.02% in 2025, then skyrocketed by 65bps to 803.29% in 2026.
  • The last three reported values for Net Margin were 803.29% (Q1 2026), 2266.02% (Q4 2025), and 124.62% (Q3 2025) per Business Quant data.